Changes in the levels of some acute‐phase proteins in human immunodeficiency virus‐1 infected patients, following interleukin‐2 treatment

V. Barbai,E. Újhelyi,J. Szlávik,I. Vietorisz,L. Varga,E. Fey,G. Füst,D. Bánhegyi

DOI: https://doi.org/10.1111/j.1365-2249.2010.04145.x

2010-07-01

Abstract:Intermittent interleukin (IL)‐2 administration to human immunodeficiency virus (HIV)‐1 infected patients is well documented and generally used, but there is limited information about the changes of acute‐phase protein (APP) levels in response to this treatment. Fifteen patients undergoing highly active anti‐retroviral therapy (HAART) treatment, with undetectable viral load, but low CD4+ cell count (<300/µl), have been treated with 3·6 M IU Proleukine® administered twice daily by subcutaneous injection over 5 days. C‐reactive protein (CRP), d‐dimer, C3, C9, C1‐inh and alpha‐2HS glycoprotein levels were measured immediately before IL‐2 administration, as well as on day 5 and 2–3 weeks thereafter. After IL‐2 administration, both mean d‐dimer and CRP levels increased significantly (P < 0·001), but returned (P < 0·001) to baseline within the subsequent 2–3 weeks. Alpha‐2HS glycoprotein decreased immediately after IL‐2 administration. No significant differences were detected in the levels of C3, C9 and C1‐inh. A significant, positive correlation (r = 0·5178, P = 0·0008) was ascertained between the changes of CRP level, measured immediately before as well as 5 days after IL‐2 administration, and changes in CD4 T cell counts measured 2–3 weeks before and after treatment, respectively. IL‐2 administration induces rapid elevation of two major APPs (CRP, d‐dimer). The positive correlation observed between the changes of CRP levels and CD4+ cell counts after IL‐2 administration may indicate that the abrupt, but transitory overproduction of CRP might contribute to the CD4+ cell count‐increasing effect of the drug and/ or may be associated with serious side effects.